Lataa...

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab

Hyperprogression is a pattern of accelerated tumor growth noted uncommonly after the use of immune checkpoint inhibitors in some patients. We present a 56-year-old female with gastroesophageal junction (GEJ) adenocarcinoma who was initially treated with neoadjuvant radiation and chemotherapy with ca...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cureus
Päätekijät: Sama, Shashank, Hadfield, Matthew J, Lopetegui Lia, Nerea, Vredenburgh, James
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Cureus 2019
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6684307/
https://ncbi.nlm.nih.gov/pubmed/31410344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.4862
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!